vs
Essex Property Trust（ESS）与ICU MEDICAL INC（ICUI）财务数据对比。点击上方公司名可切换其他公司
ICU MEDICAL INC的季度营收约是Essex Property Trust的1.1倍（$540.7M vs $479.6M），Essex Property Trust净利率更高（17.9% vs -2.9%，领先20.8%），Essex Property Trust同比增速更快（5.5% vs -14.1%），过去两年Essex Property Trust的营收复合增速更高（6.0% vs -2.3%）
Essex Property Trust是一家公开上市的房地产投资信托企业，重点布局美国西海岸优质不动产市场，核心投资标的为加利福尼亚州及西雅图大都会区的公寓类物业，在长租公寓的投资、运营及管理领域拥有深厚的行业积累与资源优势。
ICU医疗是总部位于美国加利福尼亚州圣克莱门特的医疗科技企业，专注于研发预防血流感染、保护医护人员免受传染病或危险药物侵害的医疗产品，产品线覆盖静脉治疗用品、输液泵、无针血管通路设备、定制输液套装、危险药物密闭处理系统、传感导管以及无针封闭式血液采样系统等。
ESS vs ICUI — 直观对比
营收规模更大
ICUI
是对方的1.1倍
$479.6M
营收增速更快
ESS
高出19.7%
-14.1%
净利率更高
ESS
高出20.8%
-2.9%
两年增速更快
ESS
近两年复合增速
-2.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $479.6M | $540.7M |
| 净利润 | $85.7M | $-15.7M |
| 毛利率 | 70.0% | 37.5% |
| 营业利润率 | 31.7% | 1.0% |
| 净利率 | 17.9% | -2.9% |
| 营收同比 | 5.5% | -14.1% |
| 净利润同比 | -71.6% | 34.0% |
| 每股收益（稀释后） | $1.24 | $-0.63 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESSICUI
| Q4 25 | $479.6M | $540.7M | ||
| Q3 25 | $473.3M | $537.0M | ||
| Q2 25 | $469.8M | $548.9M | ||
| Q1 25 | $464.6M | $604.7M | ||
| Q4 24 | $454.5M | $629.8M | ||
| Q3 24 | $450.7M | $589.1M | ||
| Q2 24 | $442.4M | $596.5M | ||
| Q1 24 | $426.9M | $566.7M |
净利润ESSICUI
| Q4 25 | $85.7M | $-15.7M | ||
| Q3 25 | $172.7M | $-3.4M | ||
| Q2 25 | $231.5M | $35.3M | ||
| Q1 25 | $212.8M | $-15.5M | ||
| Q4 24 | $301.7M | $-23.8M | ||
| Q3 24 | $125.5M | $-33.0M | ||
| Q2 24 | $99.0M | $-21.4M | ||
| Q1 24 | $285.1M | $-39.5M |
毛利率ESSICUI
| Q4 25 | 70.0% | 37.5% | ||
| Q3 25 | 69.2% | 37.4% | ||
| Q2 25 | 70.7% | 37.9% | ||
| Q1 25 | 69.6% | 34.7% | ||
| Q4 24 | 70.0% | 36.1% | ||
| Q3 24 | 69.5% | 34.8% | ||
| Q2 24 | 70.8% | 34.8% | ||
| Q1 24 | 69.7% | 32.7% |
营业利润率ESSICUI
| Q4 25 | 31.7% | 1.0% | ||
| Q3 25 | 44.5% | 2.6% | ||
| Q2 25 | 59.5% | 1.9% | ||
| Q1 25 | 55.3% | 2.1% | ||
| Q4 24 | 67.0% | 6.0% | ||
| Q3 24 | 28.6% | 1.4% | ||
| Q2 24 | 31.1% | 1.3% | ||
| Q1 24 | 31.0% | -1.9% |
净利率ESSICUI
| Q4 25 | 17.9% | -2.9% | ||
| Q3 25 | 36.5% | -0.6% | ||
| Q2 25 | 49.3% | 6.4% | ||
| Q1 25 | 45.8% | -2.6% | ||
| Q4 24 | 66.4% | -3.8% | ||
| Q3 24 | 27.8% | -5.6% | ||
| Q2 24 | 22.4% | -3.6% | ||
| Q1 24 | 66.8% | -7.0% |
每股收益（稀释后）ESSICUI
| Q4 25 | $1.24 | $-0.63 | ||
| Q3 25 | $2.56 | $-0.14 | ||
| Q2 25 | $3.44 | $1.43 | ||
| Q1 25 | $3.16 | $-0.63 | ||
| Q4 24 | $4.00 | $-0.97 | ||
| Q3 24 | $1.84 | $-1.35 | ||
| Q2 24 | $1.45 | $-0.88 | ||
| Q1 24 | $4.25 | $-1.63 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $76.2M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $5.5B | $2.1B |
| 总资产 | $13.2B | $4.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ESSICUI
| Q4 25 | $76.2M | — | ||
| Q3 25 | $66.0M | — | ||
| Q2 25 | $58.7M | — | ||
| Q1 25 | $98.7M | — | ||
| Q4 24 | $66.8M | $308.6M | ||
| Q3 24 | $71.3M | $312.5M | ||
| Q2 24 | $55.2M | $302.6M | ||
| Q1 24 | $499.0M | $251.4M |
总债务ESSICUI
| Q4 25 | — | — | ||
| Q3 25 | $6.4B | — | ||
| Q2 25 | $6.4B | — | ||
| Q1 25 | $6.8B | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $6.4B | — | ||
| Q2 24 | $6.2B | — | ||
| Q1 24 | $6.6B | — |
股东权益ESSICUI
| Q4 25 | $5.5B | $2.1B | ||
| Q3 25 | $5.6B | $2.1B | ||
| Q2 25 | $5.6B | $2.1B | ||
| Q1 25 | $5.6B | $2.0B | ||
| Q4 24 | $5.5B | $2.0B | ||
| Q3 24 | $5.4B | $2.0B | ||
| Q2 24 | $5.5B | $2.0B | ||
| Q1 24 | $5.5B | $2.1B |
总资产ESSICUI
| Q4 25 | $13.2B | $4.1B | ||
| Q3 25 | $13.2B | $4.1B | ||
| Q2 25 | $13.2B | $4.1B | ||
| Q1 25 | $13.2B | $4.2B | ||
| Q4 24 | $12.9B | $4.2B | ||
| Q3 24 | $12.6B | $4.3B | ||
| Q2 24 | $12.5B | $4.3B | ||
| Q1 24 | $12.9B | $4.3B |
负债/权益比ESSICUI
| Q4 25 | — | — | ||
| Q3 25 | 1.15× | — | ||
| Q2 25 | 1.14× | — | ||
| Q1 25 | 1.22× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.18× | — | ||
| Q2 24 | 1.13× | — | ||
| Q1 24 | 1.19× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.1B | $60.6M |
| 自由现金流经营现金流 - 资本支出 | — | $36.0M |
| 自由现金流率自由现金流/营收 | — | 6.6% |
| 资本支出强度资本支出/营收 | — | 4.6% |
| 现金转化率经营现金流/净利润 | 12.53× | — |
| 过去12个月自由现金流最近4个季度 | — | $91.8M |
8季度趋势，按日历期对齐
经营现金流ESSICUI
| Q4 25 | $1.1B | $60.6M | ||
| Q3 25 | $342.6M | $56.7M | ||
| Q2 25 | $216.1M | $11.2M | ||
| Q1 25 | $281.5M | $51.3M | ||
| Q4 24 | $1.1B | $40.2M | ||
| Q3 24 | $316.2M | $36.1M | ||
| Q2 24 | $218.9M | $82.0M | ||
| Q1 24 | $314.9M | $45.8M |
自由现金流ESSICUI
| Q4 25 | — | $36.0M | ||
| Q3 25 | — | $27.6M | ||
| Q2 25 | — | $-8.5M | ||
| Q1 25 | — | $36.7M | ||
| Q4 24 | — | $16.1M | ||
| Q3 24 | — | $16.2M | ||
| Q2 24 | — | $62.5M | ||
| Q1 24 | — | $29.9M |
自由现金流率ESSICUI
| Q4 25 | — | 6.6% | ||
| Q3 25 | — | 5.1% | ||
| Q2 25 | — | -1.5% | ||
| Q1 25 | — | 6.1% | ||
| Q4 24 | — | 2.6% | ||
| Q3 24 | — | 2.7% | ||
| Q2 24 | — | 10.5% | ||
| Q1 24 | — | 5.3% |
资本支出强度ESSICUI
| Q4 25 | — | 4.6% | ||
| Q3 25 | — | 5.4% | ||
| Q2 25 | — | 3.6% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | — | 3.8% | ||
| Q3 24 | — | 3.4% | ||
| Q2 24 | — | 3.3% | ||
| Q1 24 | — | 2.8% |
现金转化率ESSICUI
| Q4 25 | 12.53× | — | ||
| Q3 25 | 1.98× | — | ||
| Q2 25 | 0.93× | 0.32× | ||
| Q1 25 | 1.32× | — | ||
| Q4 24 | 3.54× | — | ||
| Q3 24 | 2.52× | — | ||
| Q2 24 | 2.21× | — | ||
| Q1 24 | 1.10× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESS
暂无分部数据
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
